Prevention Of Respiratory Distress Syndrome In Premature Infants Therapeutics
1. Surfaxin patent expiration
Treatment: Prevention of respiratory distress (rds) in premature infants
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5407914 | LEES PHARM HK | Pulmonary surfactant protein and related polypeptides |
Nov, 2013
(12 years ago) | |
Drugs and Companies using LUCINACTANT ingredient
Market Authorisation Date: 06 March, 2012
Dosage: SUSPENSION
More Information on Dosage
SURFAXIN family patents
